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Hundreds of thousands of clinical trials are conducted annually around the world, working to
further scientific knowledge and expand medical treatment. At the same time, clinical trials also
present novel challenges to researchers who have access to large pools of research participants and
are routinely approached by pharmaceutical companies seeking to recruit subjects for clinical
trials. This case study discusses the ethical dilemmas faced by a community health investigator
who received an invitation to enroll people who inject drugs (PWID) into a clinical trial of a drug
that promised a new treatment option for Hepatitis C. The author elaborates on the ethical tensions
that he confronted between “doing good” and “avoiding harm. The paper suggests that issues of
distributive justice should also be considered, particularly when the drugs being tested might
eventually command prices that place them out of reach of the population enrolled in the trial. This
case does not attempt to provide an ethical road map to assist researchers in similar circumstances,
but rather to illustrate some of the considerations involved in making a decision about whether or
not to participate in clinical trials research.
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Recently, I was approached by an investigator who wanted to enroll participants from a
community health study that I was conducting of HIV and Hepatitis C risk among people
who inject drugs (PWID). He wished to include them in an interventional clinical trial to
find out whether they could adhere to and complete an experimental drug to treat Hepatitis
C. There had been debates about whether this population would be able to follow an HCV
drug regime, which involved taking 1 pill each day for 90 days. In addition, this
interventional trial aimed to test whether participants would be able to avoid reinfection once
they had completed the HCV treatment. Reinfection could occur if they were to enter into
contact with the HCV virus either through contaminated syringes or injection equipment.
*
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These were valid and important scientific questions that would produce valuable data
regarding PWID and HCV treatment outcomes.
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The drugs to be used were in Phase III of clinical testing; they had shown promising safety
and efficacy results but had not yet been approved. A majority of participants in my study,
around 80%, had tested positive for the Hepatitis C virus. This is not surprising given that
Hepatitis C has reached epidemic levels in this population (Abadie, Welch-Lazoritz, GelpiAcosta, Reyes, & Dombrowski, 2016; Abadie, Welch-Lazoritz, Khan, & Dombrowski,
2017). Having access to more than 300 participants with a high prevalence of Hepatitis C
made my study an interesting target for clinical research. In turn, participants with a
Hepatitis C–positive, or reactive, result were also very interested in accessing treatment.
While HIV transmission—or avoiding “the monster,” as they informally call the virus—was
participants’ main concern, they were visibly distressed after learning of a positive Hepatitis
C result. Some cried when they learned that they had the virus, and I heard others praying
and thanking God effusively after learning that they were free of it.
The drugs involved in this interventional clinical trial mimic the action of drugs that had
recently been approved, revolutionizing the treatment of Hepatitis C patients. That treatment
is expensive, however, costing US$1,000 per pill; neither Medic-aid nor Medicare covers the
drug regimen in the area where I was doing the study, leaving patients infected with the virus
and, in most cases, unable to access treatment without private insurance. Only if they were
to reach an advanced stage of the disease would medical treatment become available.
Enrolling them in this trial might well be the only opportunity many of them would have to
access a potentially life-saving drug course. If everything went well, participants in the trial
could be free of Hepatitis C in 3 months.

Author Manuscript

Yet I struggled to make my decision. First, I had a number of practical concerns about
enrolling study participants in this trial because it would engender a significant disruption in
our daily research activities. As a small team, we don’t possess the capabilities to recruit
participants for a large Phase III trial, which would involve activities such as collecting
blood samples and dispensing medications to participants on a daily basis for almost a year.
This would be a significant commitment, and new funding assumed by the trial’s sponsor
would be required to cover costs since our federal funding had very strict conditions
preventing us from engaging in any activity unrelated to the original study aims.

Author Manuscript

An additional concern was that since our participants had only consented to be enrolled in
our community health study, their participation in the clinical trial would require a new
submission to the Institutional Review Board (IRB) with a corresponding consent form,
carefully explaining the goals, risks, and benefits of this new trial. Because the consent form
that participants had signed when they joined our present study had not mentioned
involvement in any other research, we could not simply invite them to participate in the
clinical trial.
Even before prospective participants could give their consent to participate, however, the
new study itself had to be submitted to the IRB and then approved. In this case, the IRB
would be not an independent body located in an academic setting but an “in-house” IRB
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funded by the trial’s sponsor. While this arrangement is not unusual in industry-sponsored
clinical trials, the ties with the pharmaceutical industry gave me pause. Because they act
much more quickly than do academic IRBs, and with much less oversight, critics argue that
these industry-sponsored IRBs often do not go beyond rubber-stamping protocols.
Given these concerns, I had to take extra care in analyzing the research protocol, paying
attention to anything that might compromise study participants. Suddenly, I realized that I
had become a de facto gatekeeper. My refusal to enter into an agreement with the study
sponsor would effectively end the possibility of conducting this trial on this population. The
pharmaceutical company that sponsored the trial would then be forced to find another
researcher with access to the population it was targeting or suspend the trial altogether.

Author Manuscript

But my most serious concerns were not instrumental, but ethical. While I am not a
physician, as a researcher I still have a fiduciary duty to do good and to protect participants
enrolled in my study from harm. While any treatment involves risks, a clinical trial, even in
its last stage, brings new risks; finding out the nature of these risks and their seriousness is
precisely the reason why clinical trials are conducted in the first place. To complicate
matters further, my knowledge of the latest treatments for Hepatitis C and related clinical
trial outcomes is limited. I wanted to contribute to a promising and well-designed scientific
protocol that could produce relevant data about HCV treatment of PWID, as well as to
ensure placement in a promising drug course for study participants. But I needed to be
reassured that participants would not be harmed by their trial participation.

Author Manuscript

If I were to decide that the risk/benefit equation was acceptable and that there were clear
gains to be had by entering this trial, should I actively recommend doing so to my study
participants? On the one hand, I was inclined to enroll them in a trial that would provide
access to an otherwise unavailable HCV drug treatment. But, on the other hand, I struggled
to recommend this course of action. My obligation toward study participants was to inform
them about the possibility afforded by this new Phase III trial, allowing them to then make
an autonomous decision about whether or not to enroll. Should I go beyond this, deciding to
participate in the clinical trial first and then actively recommending enrollment to
prospective research subjects? But would it be paternalistic to recommend that vulnerable
participants enroll in such a trial, even if the benefits clearly seemed to outweigh the risks?
And then a related worry arose. Would it be a conflict of interest to recommend their
enrollment in the clinical trial, since not only would I be associated with it, but I would also
benefit?

Author Manuscript

This dilemma kept me awake many nights: Would it be better to take a cautionary approach,
waiting until the drug was finally approved, hoping that prices could be lowered over the
years, or should I jump at what might well be the participants’ only chance to access a drug
regimen that might cure them?

Clinical Trials for Hepatitis C Drugs
Hepatitis C is a viral infection of the liver than can cause cirrhosis and liver cancer. The
virus is transmitted through blood and, at least in the US, affects mainly people who inject
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drugs through shared needles and other injection equipment. Until recently, treatment
involved injecting an extremely toxic drug for more than a year. Many patients interrupted
their drug course midway due to side effects; of those who completed it, fewer than half
were free of the virus. In 2013, the FDA approved a new polymerase-inhibiting drug that
interrupts the mechanisms the virus uses to replicate in the body, thus revolutionizing the
treatment of Hepatitis C. But it comes with sticker shock: US$80,000 dollars for the entire
3-month treatment course.

Author Manuscript

Inspired by this scientific achievement and enticed by the prospect of an extremely lucrative
market for the new polymerase- and protease-inhibiting hepatitis drugs, pharmaceutical
companies competed to produce similar formulations. Today, a number of drugs can be used
in combination to effectively treat Hepatitis C, and others are being developed. Before
reaching the market, however, all new drugs must undergo extensive clinical trials to prove
that they are safe and effective. Most clinical trials in the US or abroad currently are not
conducted by the pharmaceutical companies directly, but are outsourced to contract research
organizations (CROs) that compete with each other, all promising to navigate around ethical
and regulatory obstacles (Petryna, 2009).
None of these novel life-saving Hepatitis C drugs could have been developed without the
participation of clinical trial research subjects. It should come as no surprise, then, that the
ability to recruit a large pool of subjects has become a competitive advantage pursued by
CROs in their search for business opportunities (Fisher, 2008). The faster that willing and
able research subjects can be recruited, the sooner a clinical trial can begin. Since bringing a
drug to market already takes many years, delays in subject recruitment can further extend the
development and testing process. Time is literally money (Abadie, 2010).

Author Manuscript

Now the opportunity to enroll study participants was knocking at my door. I could see the
potential to advance clinical research, but I could not avoid thinking about the possible risks.
As a non-physician, much less an expert on Hepatitis C, how could I make the correct
decision?

Ethical Dilemmas: Beneficence versus Non-Maleficence

Author Manuscript

I struggled with this issue for many days. The tension between potentially helping
participants enrolled in my research, and my concerns that the clinical trial might harm them
because the drug was still undergoing testing and had yet to be approved, reflects two wellknown bioethical principles: beneficence and non-maleficence. Beneficence is the obligation
to do good, or to help, and involves a calculation of the relationship between risk and
benefit. Non-maleficence stresses the avoidance of doing harm (Beauchamp & Childress,
2001).
Initially, I felt overwhelmed by the responsibility presented by these two competing
obligations. On the one hand, I have a responsibility to do good, or to help participants
enrolled in my study. While it was not my obligation as a researcher, facilitating access to a
life-saving drug that otherwise would not be available to them would be an unmitigated
good. And if the trial proved successful, it would provide scientific evidence that treating
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PWID with this drug regimen was both feasible and effective, a finding that could
potentially open new therapeutic opportunities for this population.
On the other hand, I was also obliged to protect study participants from harm by avoiding
doing anything that would place their lives or well-being at risk. Unfortunately, this
obligation is more clearly defined in the case of physicians than it is for biomedical
researchers. How are we to understand harm in a context not of treatment but of research
participation, and, more importantly, how do we balance the competing obligations of
beneficence and non-maleficence?

Author Manuscript

An important condition to consider is that benefits should outweigh risks (Levine, 1986;
Emmanuel, Wendler, & Grady, 2000; Freedman, Fuks, & Weijer, 1992). Clearly, a situation
in which subjects bear risks without receiving corresponding benefits should not be
considered. But while the burden of risk falls always onto individual trial participants, the
benefits can extend beyond the individual who undergoes the clinical trial (World Health
Organization, 2001; Weijer & Miller, 2004; Sieber & Tolich, 2013). In the case of such
“social benefits,” it might be ethical to subject a consenting individual to a high level of risk
if this correlates with a potentially high benefit for society as a whole. Given what was
known about this drug, it seemed that the benefits could outweigh the risks since it could
add another powerful therapeutic weapon to the arsenal of Hepatitis C treatment while
showing apparently no more risks than the drugs that had already been approved.

Author Manuscript

I felt reassured by the fact that the drug to be tested mimicked the action of those that were
already on the market and that constituted the standard of care for this condition. According
to the data already reported in Phases I and II, the drug seemed to be safe with few side
effects, and highly effective. The trial would yield evidence about HCV treatment outcomes
among PWID while providing a good opportunity to make available an otherwise
unaffordable course of drugs to poor drug injectors living with Hepatitis C. After much
thought, I was leaning toward agreeing to involve study participants in this clinical trial.

Author Manuscript

But I struggled with an additional concern. Would it violate participants’ autonomy if I
strongly recommended this course of action for them? I did not want to force or coerce them
into participating in this trial in any way. In addition, I was also aware of the possible
conflict of interest involved, since I would receive financial compensation from the
pharmaceutical sponsor to cover operating costs. One possible approach would be to present
the information about the trial to study participants and let them make an informed and
autonomous decision about whether or not they wanted to participate. But I believed that in
this case, my goals and the interests of study participants were aligned and that no coercion
was involved. One might discount this view, finding it paternalistic (or worse, authoritarian)
based on the argument that the principle of beneficence should not override research
subjects’ autonomy. But how free or voluntary is consent once a participant is informed that
this might be his or her only opportunity to access treatment? In particular, I wanted to avoid
transmitting to study participants the idea that they would be involved in the trial simply to
receive treatment. Clearly, this should not be the goal behind their participation; doing so
would involve falling prey to the therapeutic misconception.
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The fight to bring life-saving HIV therapies to market provides a good model for thinking
about this ethical problem. Instead of opposing the principle of beneficence to the research
subjects’ right to autonomy, the history of AIDS activism shows that researchers, disease
activists, and patients can form alliances not only to further pharmaceutical research, but
also to make sure that the benefits of this research would not price out millions of potential
patients. I see myself as a disease activist following in the footsteps of AIDS researchers
who, decades ago, made the decision to strategically engage with the pharmaceutical
industry in order to test promising protease inhibitors. I would argue that prospective trial
participants are not coerced into enrolling; rather, they are in a position to make the
conscious decision to try to gain access to treatment that they otherwise could not afford.

Author Manuscript

Still, there was something about the extremely high price of these new types of HCV drugs
that gave me pause. Could I ask study participants to join a clinical trial that, if successful,
would produce a drug that most PWID might not be able to afford?

Pricing Politics

Author Manuscript

While patients and clinicians are excited about these new inhibitor drugs, their high prices—
sometimes US$100,000 or more—are a concern to everybody from insurers to health policy
experts to disease advocates. Of 10 drugs that start preclinical tests, only 1 completes the
whole process and is approved as not only safe but also effective. Therefore, those that reach
the market not only have to pay back the research costs incurred over the many years of their
own development but also must support the cost of the drugs that fail. Some critics argue,
however, that research costs are highly overestimated by the industry and that most expenses
go to marketing and not to drug research (Angell, 2005). Others suggest that drug prices do
not only reflect the economics of drug production, or the laws of supply and demand, but are
a political calculation, reflecting not what the drug actually costs but how much the industry
thinks it can get away with charging. The Nobel Prize in Economics winner Jeffery Sachs
recently estimated in his Huffington Post blog that Gilead, the maker of Sovaldi, one of the
drugs that has become the standard of care for HCV treatment, spent only $US500 to
produce a drug that it is selling for close to US$1,000 dollars per pill (Sachs, 2016).
Reacting to the controversy, Gilead argued that the high price reflected research costs, but it
also made an agreement with many developing countries to provide the drug at a very steep
discount.

Author Manuscript

Millions of patients all over the world are infected with the Hepatitis C virus, and it is
particularly rampant among PWID; some observers consider Hepatitis C to be an epidemic
among this population (Aceijas & Rhodes, 2007; Bao & Li, 2009). Such high prices make it
extremely hard to treat all of those who need the drug most. Developing countries can go
bankrupt trying to cover such costs, but even in rich countries such high prices place a big
strain on healthcare budgets, private insurance, and HMOs (Hill, Khoo, & Fortunak, 2014).
It is tragic that exorbitant Hepatitis C prices place life-saving drugs out of reach for millions
of patients. Untreated, many will suffer and possibly experience a preventable death.

Narrat Inq Bioeth. Author manuscript; available in PMC 2017 August 23.

Abadie

Page 7

Author Manuscript

A Way Forward
With an increasing number of clinical trials designed to bring new drugs into their research
pipelines, pharmaceutical companies will continue to contact researchers regarding access to
large pools of potential subjects. While all researchers face the same considerations, nonphysician researchers confront a particular set of dilemmas and obligations with even less
ethical guidance. I have noted one main tension, that between the obligation to help research
participants, or beneficence, and the obligation to do no harm, or non-maleficence. While
there is no simple solution to this dilemma, I hope that this narrative provides some guidance
to those who find themselves in a similar position.

Author Manuscript

What motivated me to consider the possibility of enrolling study participants in this trial in
the first place was the opportunity to answer a valid scientific question regarding the ability
of PWID to successfully complete a full HCV course while avoiding reinfection.
Additionally, I was intrigued by the possibility that a well-designed Hepatitis C clinical trial
might be the best way to provide these patients with access to a potentially life-saving drug.
Finally, I also recognized that if the trial was successful, it would strengthen the drug arsenal
available to treat Hepatitis C, and competition for market share would contribute to lowering
its price.

Author Manuscript

With a therapy carrying such a high price tag, the issue of access cannot be avoided. While
the ethical principles of beneficence, non-maleficence, and autonomy are part of any toolkit
of bioethics analysis, the principle of justice often does not receive the same degree of
attention. In particular, questions of distributive justice—who has access or who receives
which kind of treatment (Rawls, 1971)—are especially salient in this case, in which poor
PWID are being asked to assume the risks of enrolling in a clinical trial for HCV. For those
lucky enough to complete the drug regimen and avoid reinfection, becoming free of HCV is
indeed a great outcome. But what about the millions of PWID in the US and abroad who
struggle to obtain HCV treatment? Would they be able to afford the new drugs at these
prices?

Author Manuscript

While it is true that a full HCV drug course is still cheaper than a liver transplant, we can
and should do more to ensure treatment access, perhaps borrowing a road map from AIDS
activism (Farmer, 2014). While antiretroviral therapy was initially extremely expensive, the
involvement of community activists and governmental intervention through subsidies and
patent-breaking laws together led to a dramatic reduction in prices and an increase in drug
availability (Biehl, 2009). But an important role was also played by researchers, who allied
with HIV patients and their advocates and used clinical trials as an opportunity not only to
produce scientific knowledge about treatment, but also to expand therapeutic opportunities
for patients.

Postscript
The reader might wonder what happened with the trial that I was invited to join. The answer
is: nothing. Although I had concluded that this was something that I wanted to explore
further, after a few initial conversations about the conditions of our collaboration, the contact
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from the CRO disappeared without a trace. I don’t know if the trial will be conducted among
another population in the same area, or if it will be conducted elsewhere, or be discarded
altogether. Clinical trials can provide valuable opportunities to contribute to scientific
knowledge, and may allow patients to test new treatments or novel drugs, but in all cases
their benefits should be weighed against their risks.

Reflection Questions

Author Manuscript

1.

Since they were originally formulated a few decades ago, the principle of respect
for autonomy seems to have gained priority in detriment of the principle of
justice. With drug prices reaching exorbitant levels—more than eighty thousand
dollars for a full HCV treatment—placing access beyond the reach of many,
shouldn’t bioethicists reconsider the way we think about justice?

2.

The principle of beneficence establishes the requirement of a social good, as one
of if its main criteria. But drug prices seem to benefit the pharmaceutical industry
while depriving many of much needed drugs. With this in mind, how do you
think we should interpret this principle?

3.

Imagine you or somebody you know has the opportunity to participate in a
clinical trial. What elements would you need in order to make an informed
decision? And an ethical one?
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